Navigation Links
Discovery of relationship between proteins may impact development of cancer therapies
Date:4/19/2011

By identifying a surprising association of two intracellular proteins, University of Iowa researchers have laid the groundwork for the development of new therapies to treat B cell lymphomas and autoimmune disease.

The researchers studied mouse B cells expressing the viral protein Latent Membrane Protein 1 (LMP1), which has been implicated in several types of cancer because of its role in the proliferation and survival of Epstein-Barr virus infected B cells. They discovered that LMP1 needs the cellular protein Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) to promote its B cell activation signaling pathways.

The study, published recently in the Journal of Biological Chemistry, also shows that LMP1 and CD40 a normal activating receptor of B cells both use TRAF6 as a key signaling protein, but in different ways. LMP1 mimics CD40 in delivering activation signals to B cells, but LMP1's signals are amplified and sustained, resulting in B cell hyper-activation.

B cells are a type of white blood cell. They normally mature into plasma cells that produce proteins called antibodies necessary to fight off infections. But in the process of modifying antibody genes, mistakes can cause mutations. With an accumulation of such mutations, B cells can become cancerous, which is why B cell malignancies are relatively common.

"We found that TRAF6 is essential for LMP1 functions, and that it interacts with LMP1 in a way that is distinct from the way in which TRAF6 interacts with CD40," said lead author Kelly Arcipowski, a Ph.D. candidate in the UI Molecular and Cellular Biology Interdisciplinary Graduate Program. "Thus, it might be possible to target LMP1 signaling without disrupting normal immune function. This information is valuable to the development of new therapies to target LMP1-mediated pathogenesis, including B cell lymphomas and autoimmune disease."

B-cell lymphomas include Hodgkin's lymphomas and most non-Hodgkin's lymphomas. Examples of autoimmune diseases in which LMP1 is implicated are rheumatoid arthritis and systemic lupus erythematosus (SLE).

LMP1 is produced by a normally latent gene that is expressed when Epstein-Barr virus, a herpes virus that infects greater than 90 percent of humans, becomes reactivated from its inactive state. This can occur in flares of autoimmune disease, and in people who are immune-deficient. Epstein-Barr virus can thus become activated in cases of late-stage AIDS or organ and bone marrow transplant recipients who are immunosuppressed to prevent rejection of the transplant.

While LMP1 contributes to the formation of a tumor, it isn't an ideal target for therapeutics. LMP1 is a protein that is being constantly internalized from the cell surface, prompting researchers to instead target the signaling pathway.

"(Researchers) first thought you would be targeting the normal protein (CD40), too," said senior study author Gail Bishop, Ph.D., professor of microbiology at the UI Carver College of Medicine and director of the Immunology Interdisciplinary Graduate Program. "What our lab has discovered over the years is that LMP1 produces CD40-like effects using the same proteins in different ways, and therefore that opens a window to targeting just LMP1."

Arcipowski currently is researching how TRAF6 is activating the LMP1 signaling pathway. "If you figured out exactly which part of TRAF6 was binding to LMP1, you could target that specific interaction while leaving TRAF6's association with CD40 intact," Arcipowski said.


'/>"/>

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-356-7124
University of Iowa Health Care
Source:Eurekalert

Related medicine news :

1. Discovery of 2 new genes provides hope for stemming Staph infections
2. New discovery proves cause of weight problems in Huntingtons disease
3. A safer, more effective morphine may be possible with Indiana University discovery
4. Discovery in liver cancer cells provides new target for drugs
5. Finding of long-sought drug target structure may expedite drug discovery
6. New laser technique opens doors for drug discovery
7. LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus
8. Clinical observation leads to lung cancer discovery
9. New weight loss discovery by Harvard scientists moves us closer to the Pill for obesity
10. Leicester leads on heart attack genetic link discovery
11. Discovery of new gene mutation in schizophrenia offers a new target for drug therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... The California State University Institute for Palliative Care ... or interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: ... San Diego on Sept. 28 and 29, 2017, on the campus of California State ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... ... 2017 , ... The Radiology Business Management Association will select the ... annual Building Better Radiology Marketing Programs conference, held this year from March ... Nine awards are given out in five categories. They are:, , ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the ... The Jensie Gran Fondo of Marin. For the second year in a row, ... mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Oesophageal ... their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis and Strategies - ... Cancer market. The research answers the following questions: ... Oesophageal Cancer and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... 23, 2017 Regulus Therapeutics Inc . ... development of innovative medicines targeting microRNAs, today announced it ... results on Thursday, March 2, 2017 after the market ... and webcast on March 2, 2017 at 5:00 p.m. ... 2016 financial results and provide a general business update.  ...
Breaking Medicine Technology: